EUVIMEDOpdag EUVIMED
Crossref

Some Risks of Gastrointestinal Adverse Events Associated With Glucagon‐Like PEPTIDE‐1 Receptor Agonists Are Likely Explained by BMI

Benjamin Douglas Liu iD, Donovan Veccia, Yan Sun, Gengqing Song

Alimentary Pharmacology & Therapeutics · 2025

DOI: 10.1111/apt.70190 ↗

At a glance

Journal article in Alimentary Pharmacology & Therapeutics, 2025. Written by Benjamin Douglas Liu and 3 co-authors. Institution: Department of Medicine, MetroHealth Medical Center, Case Western Reserve University, Cleveland, Ohio, USA. Major MEDLINE topics: Glucagon-Like Peptide-1 Receptor Agonists, Body Mass Index, Obesity, Gastrointestinal Diseases. Cited 3 times so far (Crossref); 5 references.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

We performed a re‐analysis of the gastrointestinal risks of glucagon‐like peptide‐1 receptor agonists (GLP‐1 RA) in obese US adult patients without diabetes using the TriNetX database (GLP‐1 RA n = 8792; Bupropion‐naltrexone n = 8792) after accounting for initial BMI. GLP‐1 RA users had higher risks of gastroparesis (aHR 2.30; 95% CI 1.19–4.46) and biliary disease (aHR 1.27; 95% CI 0.96–1.39) but did not have a conclusively elevated risk of acute pancreatitis or obstruction. Not matching for BMI suggested an elevated pancreatitis risk (aHR 1.75; 95% CI 1.13–2.70). Semaglutide conferred superior weight loss but increased biliary risk.

Subjects

MeSH terms (MEDLINE)

Glucagon-Like Peptide-1 Receptor AgonistsBody Mass IndexObesityGastrointestinal DiseasesHypoglycemic AgentsHumansFemaleMaleMiddle AgedAdultGlucagon-Like PeptidesRisk FactorsAgedGlucagon-Like Peptide 1Semaglutide

Author keywords

biliary diseasebupropion‐naltrexoneglucagon‐like Peptide‐1 receptor agonistpancreatitisweight loss

Substances

Glucagon-Like Peptide-1 Receptor AgonistsHypoglycemic AgentsGlucagon-Like PeptidesGlucagon-Like Peptide 1Semaglutide

Authors and institutions

  • Department of Medicine, MetroHealth Medical Center, Case Western Reserve University, Cleveland, Ohio, USA.
  • Division of Gastroenterology and Hepatology, MetroHealth Medical Center, Case Western Reserve University, Cleveland, Ohio, USA.

ORCID profiles: Benjamin Douglas Liu

Cite

APA

Liu, B. D., Veccia, D., Sun, Y., & Song, G. (2025). Some Risks of Gastrointestinal Adverse Events Associated With Glucagon‐Like PEPTIDE‐1 Receptor Agonists Are Likely Explained by BMI. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/apt.70190

Vancouver

Liu BD, Veccia D, Sun Y, Song G. Some Risks of Gastrointestinal Adverse Events Associated With Glucagon‐Like PEPTIDE‐1 Receptor Agonists Are Likely Explained by BMI. Alimentary Pharmacology & Therapeutics. 2025. doi:10.1111/apt.70190

BibTeX
@article{Liu2025,
  author = {Liu, Benjamin Douglas and Veccia, Donovan and Sun, Yan and Song, Gengqing},
  title = {Some Risks of Gastrointestinal Adverse Events Associated With Glucagon‐Like PEPTIDE‐1 Receptor Agonists Are Likely Explained by BMI},
  journal = {Alimentary Pharmacology & Therapeutics},
  year = {2025},
  doi = {10.1111/apt.70190}
}
Start for free →